Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;9(10):1283-1288.
doi: 10.1080/17512433.2016.1233059. Epub 2016 Sep 20.

Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data

Antonio Passaro  1 , Alessia Pochesci  1 , Gianluca Spitaleri  1 , Chiara Catania  1 , Cristina Noberasco  1 , Ester Del Signore  1 , Filippo de Marinis  1
Affiliations

Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data

Antonio Passaro et al. Expert Rev Clin Pharmacol. 2016 Oct.

Abstract

Epidermal growth factor receptor (EGFR) mutations are detected in about 10-15% of Caucasian and 30-40% of Asian patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In patients harbouring EGFR mutations, the treatment with different available EGFR tyrosine kinase inhibitors (TKIs) showed to be more effective and safe than platinum-based chemotherapy regimens. Areas covered: The current evidences about the role of afatinib for patients with EGFR-positive NSCLC are reviewed and discussed. We report a review based on a MEDLINE/PubMed, searched for randomized phase II or III trials evaluating afatinib in EGFR-positive NSCLC. Expert commentary: Afatinib is the third EGFR TKI approved for the treatment of NSCLC harbouring EGFR mutations, showing high efficacy in this setting of patients.

Keywords: EGFR; LUX-Lung 7; NSCLC; TKI; afatinib; dose reduction; lung cancer; tyrosine kinase inhibitor; uncommon mutation.

PubMed Disclaimer

LinkOut - more resources